



Parabolic Drugs Limited

Registered & Corporate Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Unaudited Financial Results for the Nine months Ended 31st December' 2014

(Rs. Crores)

S.no.	Particulars	Three months Ended	Preceding three months ended	Corresponding Three months Ended	Nine months Ended	Corresponding nine months ended	Previous Accounting Year ended
		31.12.2014	30.09.2014	31.12.2013 in the previous year	31.12.2014	31.12.2013 in the previous year	31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						446.71
	Gross Sales	45.18	53.30	113.48	212.11	330.53	(16.33)
	Less : Excise Duty	(2.28)	(3.67)	(5.41)	(9.94)	(12.20)	
	(a) Net Sales/Income from Operations (Net of excise duty)	42.90	49.63	108.07	202.17	318.33	430.38
	(b) Other Operating Income	0.92	0.77	6.35	2.54	12.69	20.20
2	Total Income from Operations (net)	43.82	50.40	114.42	204.71	331.02	450.58
	Expenses						
	(a) Cost of Materials Consumed	31.99	39.77	97.97	167.42	296.40	390.62
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1.64	0.40	(0.54)	2.04	(20.73)	(21.40)
	(c) Employee Benefits Expense	4.69	3.92	5.02	13.28	14.02	18.55
	(d) Depreciation & Amortisation Expense	17.19	17.26	17.03	51.68	51.06	68.08
	(e) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	8.52	10.93	10.41	28.27	33.11	131.68
3	Total Expenses	64.03	72.28	129.89	262.69	373.86	587.53
4	Profit/(Loss) from Operations before Other Income, Finance Costs & Exceptional Items (1 - 2)	(20.21)	(21.88)	(15.47)	(57.98)	(42.84)	(136.95)
5	Other Income	-	-	-	-	-	-
6	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(20.21)	(21.88)	(15.47)	(57.98)	(42.84)	(136.95)
7	Finance Costs	18.97	18.69	19.93	55.80	59.52	83.07
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(39.18)	(40.57)	(35.40)	(113.78)	(102.36)	(220.02)
9	Exceptional Items	-	-	-	-	-	-
10	Profit/(Loss) from Ordinary Activities before tax (7 + 8)	(39.18)	(40.57)	(35.40)	(113.78)	(102.36)	(220.02)
11	Tax expense	-	(12.53)	(10.94)	(23.05)	(31.63)	(61.30)
12	Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(39.18)	(28.04)	(24.46)	(90.73)	(70.73)	(158.72)
13	Extra Ordinary Items (net of tax expense)	-	-	-	-	-	(26.98)
14	Net Profit / (Loss) for the period (11-12)	(39.18)	(28.04)	(24.46)	(90.73)	(70.73)	(131.74)
15	Share of Profit/(Loss) of Associates	-	-	-	-	-	-
16	Minority Interest	-	-	-	-	-	-
17	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of Associates (13 +14 + 15)	(39.18)	(28.04)	(24.46)	(90.73)	(70.73)	(131.74)
18	Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89	61.89	61.89
19 (i)	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						226.76
	Earnings Per Share (EPS) (before extraordinary items) -Shares of Rs. 10/- each (not annualised)						
	(a) Basic	(6.33)	(4.53)	(3.95)	(14.66)	(11.43)	(21.29)
	(b) Diluted	(6.33)	(4.53)	(3.95)	(14.66)	(11.43)	(21.29)
19 (ii)	Earnings Per Share (EPS) (after extraordinary items) -Shares of Rs. 10/- each (not annualised)						
	(a) Basic	(6.33)	(4.53)	(3.95)	(14.66)	(11.43)	(21.29)
	(b) Diluted	(6.33)	(4.53)	(3.95)	(14.66)	(11.43)	(21.29)
A.	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding :						
	- Number of Shares	37,974,587	37,974,587	38,362,317	37,974,587	38,362,317	38182935



**Parabolic Drugs Limited**Registered & Corporate Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Unaudited Financial Results for the Nine months Ended 31st December' 2014

(Rs. Crores)

S.no.	Particulars	Three months Ended	Preceding three months ended	Corresponding Three months Ended	Nine months Ended	Corresponding nine months ended	Previous Accounting Year ended
		31.12.2014	30.09.2014	31.12.2013 in the previous year	31.12.2014	31.12.2013 in the previous year	31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
2	- Percentage of Shareholding	61.36	61.36	61.98	61.36	61.98	61.69
Promoters and Promoter Group Shareholding :							
(a) Pledged/Encumbered							
	- Number of shares	22,619,927	22,619,927	22,217,497	22,619,927	22,217,497	22372320
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.58	94.58	94.42	94.58	94.42	94.36
	- Percentage of shares (as a % of the total share capital of the company)	36.55	36.55	35.90	36.55	35.90	36.14
(b) Non-Encumbered							
	- Number of shares	1,297,500	1,297,500	1,312,200	1,297,500	1,312,200	1336759
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.42	5.42	5.58	5.42	5.58	5.64
	- Percentage of shares (as a % of the total share capital of the company)	2.10	2.10	2.12	2.10	2.12	2.16
B.	INVESTOR COMPLAINTS					Quarter ended	Quarter ended
						31/12/2014	31/12/2013
Pending at the beginning of the quarter						Nil	Nil
Received during the quarter						Nil	1
Disposed of during the quarter						Nil	1
Remaining unresolved at the end of the quarter						Nil	Nil

Notes :

- The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th February, 2015 and the same have been reviewed by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
- During the period under review, the company has incurred loss owing to the unfavourable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
- The promoters' shareholding has been pledged pursuant to the terms of CDR package.
- There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
- Figures of the previous year / period have been rearranged/regrouped wherever necessary.

Place : Chandigarh
Date :14th Feb., 2015

For Parabolic Drugs Ltd.

Pranav Gupta
Chairman & Managing Director

S. K. BANSAL & CO.

CHARTERED ACCOUNTANTS

Kothi No. : 3193, Sector 28-D,
Changigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.bansals.in

Phones Off. 2657202

2651578

2657644

Fax 2652428

Limited Review Report to the Board of Directors

We have reviewed the accompanying statement of unaudited financial results as enclosed of **M/s Parabolic Drugs Limited having Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh for the Quarter/nine months ended 31st December 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above subject to Annexure-A, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chandigarh;

Dated: 14th February 2015

**FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS**



(Signature)
(S.K.Bansal)
Membership No: 013147

Annexure A

Notes on the Un audited financial results of M/s Parabolic Drugs Limited

For the Quarter/nine months ended 31st December 2014

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 1956.
3. The Net Sales of Rs.202.17 crores for the nine months ended 31st December 2014 includes trading sale of Rs.58.52 crores.
4. Figures of the previous year/Quarter/nine months have been rearranged/regrouped wherever considered necessary.

**Chandigarh;
Dated: 14th February 2015**

**FOR S.K. BANSAL & CO.,
CHARTERED ACCOUNTANTS**




(S.K.Bansal)

Membership No: 013147